{"id":47145,"date":"2019-12-17T15:35:56","date_gmt":"2019-12-17T14:35:56","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=47145"},"modified":"2019-12-17T20:40:27","modified_gmt":"2019-12-17T19:40:27","slug":"astellas-compra-audentes-per-27-miliardi-di-euro","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/astellas-compra-audentes-per-27-miliardi-di-euro\/","title":{"rendered":"Astellas buys Audentes for 2.7 billion euros"},"content":{"rendered":"

The acquisition will provide the Japanese group with greater ability to create innovative drugs for diseases that require greater attention from the scientific community.<\/h3>\n

Plantadoce \u2013 17 December 2019<\/a><\/p>\n

Astellas Pharma remains determined to diversify its business area. Last year, the company has \"\"<\/a>reorganized around four areas of interest and with the acquisition of Audentes Therapeutics for 3,000 million dollars (2,693 million euros) opened a fifth, dedicated to genetic regulation.<\/p>\n

Astellas' commitment to the acquisition of the biotech company was determined. In fact, it paid a 110% premium to the share price at the close of Monday's session. The large amount for which the purchase has been formalized suggests that several companies may have shown interest in Audentes, as reported by FierceBiotech.<\/p>\n

\u201cAccelerating early-stage scientific innovation in areas such as cell and gene therapy is a strategic approach for Astellas and aligns perfectly with the mission of our launch platform for new life sciences and biotech companies,\u201d he said. Kenji. Yasukawa, president of Astellas.<\/p>","protected":false},"excerpt":{"rendered":"

L’acquisizione fornir\u00e0 al gruppo giapponese una maggiore capacit\u00e0 di creare farmaci innovativi per le malattie che richiedono maggiore attenzione da parte della comunit\u00e0 scientifica. Plantadoce – 17 dicembre 2019 Astellas Pharma rimane determinata a diversificare la propria area di business. L’anno scorso, l’azienda si \u00e8 riorganizzata attorno a quattro aree di interesse e con l’acquisizione …<\/p>","protected":false},"author":4,"featured_media":28969,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53],"class_list":["post-47145","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/47145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=47145"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/47145\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/28969"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=47145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=47145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=47145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}